Hospital Injectable Products · LP-200
Potassium chloride Injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-200Hospital Injectable Products
- Generic identity
- Potassium chlorideInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-200
- Generic ingredient
- Potassium chloride
- Dosage form
- Injection
- Proposed strength
- 2 mEq/mL
- Proposed pack
- Ampoule 10 mL; hospital use only
- Portfolio category
- Hospital Injectable Products
About Potassium chloride
Potassium chloride is an electrolyte medicine used when a clinical assessment identifies a need for potassium replacement. The source record describes a concentrated injectable ampoule. This is a high-alert hospital presentation because undiluted or incorrectly administered concentrate can be fatal. It is fundamentally different from an oral potassium product or a ready-prepared diluted infusion.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Clinical assessment considers the potassium result, symptoms, cardiac status, renal function, ongoing losses and other electrolytes. The appropriate replacement route and monitoring are professional decisions. A concentrated ampoule should be controlled through institutional procurement, storage and preparation procedures. This page does not supply a dilution recipe, administration rate, maximum concentration or infusion instruction. Its purpose is to identify the presentation and highlight the need for verified clinical and pharmacy controls.
Important safety considerations
Excess potassium can cause dangerous arrhythmia or cardiac arrest. Impaired kidney function and medicines that reduce potassium excretion increase the risk. Local tissue injury can occur with unsuitable concentration or extravasation. The concentrate must never be administered undiluted. Look-alike ampoules and confusion between total content and concentration are critical hazards. Appropriate laboratory and cardiac monitoring must be established by the treating team.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The source specifies 2 mEq/mL in a 10 mL ampoule. Keep the concentration, total content and unit convention clearly distinct. The exact concentrate label and required preparation instructions must be verified; a diluted-infusion label is not an equivalent specification.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm clinical need, renal function, interacting medicines and monitoring. Require independent product and preparation checks under a hospital high-alert electrolyte policy.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Potassium chloride
- Dosage form / presentation
- Injection
- Catalogue strength
- 2 mEq/mL
- Catalogue pack
- Ampoule 10 mL; hospital use only
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- The catalogue records potassium chloride injection at 2 mEq/mL in a 10 mL ampoule. It does not establish whether the presentation is a concentrate requiring dilution, the labelled total content, authorised route or compatibility instructions.
- Because concentrated potassium products are high-risk, no preparation or administration instruction is inferred from a comparator label.
- Approved indication, patient eligibility and dosing or test interpretation are not established by this portfolio record.
- Registration/authorization, manufacturing or site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- DailyMed: potassium chloride for injection concentrate 2 mEq/mL — external comparatorgovernment-hosted external product label
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Sterile product specification confirming exact active chemical/formulation identity, concentration, container/fill, authorised route(s), excipients/preservatives and preparation/compatibility controls.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-200, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-200.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.